DLL3 and small cell lung carcinoma: Lastly, AMG 119, a DLL3-targeting CAR-T cell therapy, has demonstrated manageable safety and preliminary efficacy signals in patients with DLL3-expressing relapsed/refractory SCLC in a phase I trial (NCT03392064) (155).